$LGCXF

A Nevada gold and silver project is projected to bring in $3.68 billion over 11 years, Lahontan Gold says.

Lahontan Gold Corp. (TSXV:LG, OTCQB:LGCXF) announced a positive Preliminary Economic Assessment for its Santa Fe Mine project in Nevada. The PEA projects a post-tax NPV5 of $820.0M, IRR of 40.1%, and $3.68B in revenue over 11 years. The project has estimated pre-production capital costs of $172.0M and a payback period of 3.7 years. The company expects to obtain necessary permits in 2027.

Original reporting
Published Oct 14, 2026, 2:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 2:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LGCXF
Bullish
medium confidence
Mentioned
$LGCXF
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LGCXFBullishLow
01

Why it matters

The strong NPV and IRR suggest the project could become a significant cash‑flow generator, potentially attracting financing and raising the stock.

02

Market read

New project economics may drive speculative buying in the junior mining space.

03

What to watch

Permitting risk and commodity price volatility could temper upside.

Relevance 5/10Novelty 7/10Timing: today

Background

The release is a first‑time disclosure of a detailed economic assessment for Lahontan's flagship Santa Fe Mine in Nevada.

Company-level read

Ticker impact

$LGCXFBullishMedium confidence
Context

Lahontan Gold Corp. announced a Preliminary Economic Assessment projecting $3.68 billion revenue over an 11‑year mine life.

Expected impact

likely upward pressure as investors price in strong economics

Evidence & confidence

The PEA shows high NPV and IRR, which are material for a junior miner and may attract capital.

Market effects

May boost interest in Nevada gold‑silver projects and junior miners.

Could improve sentiment for the broader TSXV mining sector.

Limited to mining investors; no broad market effect.

Counterpoint

If the PEA relies heavily on inferred resources, investors may remain cautious.

Key entities

  • Lahontan Gold Corp.

    Junior gold‑silver miner reporting the PEA.

  • Kappes, Cassiday & Associates

    Prepared the PEA.

Related articles

$CVXLow

Ministry of Petroleum and Mineral Resources and Chevron Announce Positive Results from Nargis-2 Well in the Mediterranean Sea

Chevron and Egypt's Ministry of Petroleum announced positive results from the Nargis-2 gas well in the Mediterranean. The well confirmed extended gas-bearing reservoirs and an additional gas interval, supporting further appraisal and development. Chevron operates the area with partners Eni, Mubadala Energy, and Tharwa Petroleum. The well reached 5,000 meters with 35 meters of net gas pay, indicating potential for further development.

$GMABMed

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab and Incyte are collaborating on clinical trials for metastatic colorectal cancer. The trials will evaluate the combination of Genmab's petosemtamab and Incyte's INCB161734 with standard chemotherapy. Petosemtamab targets EGFR and LGR5, while INCB161734 inhibits KRAS G12D. The companies aim to provide a new treatment option for patients with KRAS G12D-mutated metastatic colorectal cancer.

$INCYMedAI 8/10

Incyte and Genmab Announce Clinical Trial Collaboration in Metas

Incyte (INCY) and Genmab (GMAB) are collaborating on a clinical trial to evaluate Incyte's KRAS G12D inhibitor INCB161734 with Genmab's bispecific antibody petosemtamab and standard chemotherapy for metastatic colorectal cancer with KRAS G12D mutation. The Phase 1/2 study will be co-funded by both companies, with Genmab conducting the trial and Incyte providing the clinical supply of INCB161734. This collaboration aims to address a significant unmet medical need in this patient population.

$ALGTMed

Allegiant doubles down on Boeing 737 MAX with six more aircraft

Allegiant Travel Company exercised options for six more Boeing 737 MAX 8 aircraft, scheduled for 2028 delivery, increasing its firm commitment to 56 aircraft. The jets have a combined list price of over $720 million, with an estimated market value of $351 million. Allegiant is transitioning from Airbus to Boeing, citing lower fuel consumption and improved reliability. The company also acquired Sun Country Airlines in 2026.